Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril/Valsartan vs Ramipril in Ischemic HFmrEF
NCT05508035Phase 3Recruiting
- Sponsor
- Krakowski Szpital Specjalistyczny im. Jana Pawła II
- Start
- Jul 2023
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sacubitril + valsartan in heart failure with moderately reduced ejection fraction (HFmrEF), sponsored by Krakowski Szpital Specjalistyczny im. Jana Pawła II. Started Jul 2023; status: recruiting.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with moderately reduced ejection fraction (HFmrEF)
Beyond the preview
Go deeper on NCT05508035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05508035.